International Stem Cell Corp (ISCO): Total Assets
$4.82M
As of 2025-12-31
$5.06M
As of 2026-06-30
-2.1%
3-year compound annual growth
-1.8%
5-year compound annual growth
-3.9%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.82M | -6.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $5.17M | -4.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $5.39M | +5.0% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $5.13M | +3.8% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $4.95M | -6.4% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $5.29M | -20.1% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $6.62M | -15.1% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $7.80M | +13.6% | 2020-06-01, Balance as of period end |
| 2017-12-31 | $6.86M | -2.6% | 2019-04-15, Balance as of period end |
| 2016-12-31 | $7.04M | -1.3% | 2018-04-09, Balance as of period end |
| 2015-12-31 | $7.14M | -0.6% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $7.18M | -7.2% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $7.74M | +44.1% | 2015-03-30, Balance as of period end |
| 2012-12-31 | $5.37M | -6.4% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $5.74M | -42.2% | 2013-03-26, Balance as of period end |
| 2010-12-31 | $9.93M | n/a | 2012-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.82M | -6.8% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $294.89M | -17.7% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.00B | -5.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
Compare ISCO, BIOA, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗